306 related articles for article (PubMed ID: 19744017)
1. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
Al-Kali A; Farooq S; Tfayli A
J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
[TBL] [Abstract][Full Text] [Related]
2. Tumour lysis syndrome with acute renal failure during imatinib therapy.
Ali R; Ozkalemkas F; Ozkan A; Ozcelik T; Ozkocaman V; Akdag I; Ozan U; Tunali A
Leuk Res; 2007 Apr; 31(4):573-4. PubMed ID: 16782190
[No Abstract] [Full Text] [Related]
3. Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
Chang H; Shih LY
Chang Gung Med J; 2008; 31(5):510-4. PubMed ID: 19097599
[TBL] [Abstract][Full Text] [Related]
4. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
[TBL] [Abstract][Full Text] [Related]
5. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
Khouri S; Kotliroff A; Lishner M; Amital H
Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
[No Abstract] [Full Text] [Related]
6. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
7. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
[No Abstract] [Full Text] [Related]
8. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
Kim M; Lee S; Jung CK; Lim J; Cho SG; Kim DW; Kim Y; Han K; Min WS; Kim CC
Int J Lab Hematol; 2008 Dec; 30(6):508-12. PubMed ID: 18983302
[TBL] [Abstract][Full Text] [Related]
9. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
Wong M; Sade S; Gilbert M; Klieb HB
Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826
[TBL] [Abstract][Full Text] [Related]
10. Imatinib: a designer drug, another cutaneous complication.
Dickens E; Lewis F; Bienz N
Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
[TBL] [Abstract][Full Text] [Related]
11. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
12. [Adverse effects of imatinib mesylate].
Isshiki I
Nihon Rinsho; 2007 Jan; 65 Suppl 1():404-7. PubMed ID: 17474438
[No Abstract] [Full Text] [Related]
13. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
Scheinfeld N
J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
[TBL] [Abstract][Full Text] [Related]
14. Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.
Busuttil DP
Int J Lab Hematol; 2008 Feb; 30(1):68-70. PubMed ID: 18190471
[TBL] [Abstract][Full Text] [Related]
15. Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.
Gafter-Gvili A; Ram R; Gafter U; Shpilberg O; Raanani P
Leuk Res; 2010 Jan; 34(1):123-7. PubMed ID: 19640584
[TBL] [Abstract][Full Text] [Related]
16. Is there any protective effect on organs upon higher uric acid level in tumor lysis syndrome?
Basturk A; Hacibekiroglu T; Akinci S; Dilek I; Atalay HV
Ren Fail; 2011; 33(4):465. PubMed ID: 21529279
[No Abstract] [Full Text] [Related]
17. Irreversible sensorineural hearing loss due to Imatinib.
Attili VS; Bapsy PP; Anupama G; Lokanatha D
Leuk Res; 2008 Jun; 32(6):991-2. PubMed ID: 18221994
[TBL] [Abstract][Full Text] [Related]
18. Peripheral neuropathy as an adverse effect of imatinib therapy.
Chakupurakal G; Etti RJ; Murray JA
J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
[No Abstract] [Full Text] [Related]
19. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
Ayirookuzhi SJ; Ma L; Ramshesh P; Mills G
Arch Dermatol; 2005 Mar; 141(3):368-70. PubMed ID: 15781678
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.
Thia TJ; Tan HH; Chuah TH; Chow WC; Lui HF
Singapore Med J; 2008 Mar; 49(3):e86-9. PubMed ID: 18362995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
